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Activation of Akt at T308 and S473 in alcohol,
tobacco and HPV-induced HNSCC: is there
evidence to support a prognostic or diagnostic
role?
Mohammad R Islam1, Ian R Ellis1, Michaelina Macluskey1, Lynda Cochrane2 and Sarah J Jones1*
Abstract
Background: Tobacco, alcohol and HPV infection are associated with increased risk of HNSCC. However, little is
known about the underlying signaling events influencing risk. We aimed to investigate the relationship between
these risk factors and Akt phosphorylation, to determine prognostic value.
Method: VEGF-positive HNSCC biopsies, with known HPV status, were analyzed by immunohistochemistry (IHC)
for Akt, phosphorylated at residues S473 and T308. Comparisons between the tissues were carried out using a
Mann–Whitney U test. Associations between the variables and continuous immunohistochemical parameters
were evaluated with general linear models. Patient characteristics and pAkt IHC score were analyzed for possible
association with overall survival by Cox proportional hazard models.
Results: Immunohistochemistry revealed that cancer patients had significantly higher levels of pAkt T308 than
S473 (P < 0.001). Smoking and alcohol were found to be independent risk factors for Akt phosphorylation at T308
(P = 0.022 and 0.027, respectively). Patients with tumors positive for HPV or pAkt S473 had a poorer prognosis
(P = 0.005, and 0.004, respectively). Patients who were heavy drinkers were 49 times more likely to die than
non-drinkers (P = 0.003). Patients with low pAkt T308 were more likely to be HPV positive (P = 0.028). Non-drinkers
were also found to have lower levels of pAkt T308 and were more likely to have tumors positive for HPV than
heavy drinkers (P = 0.044 and 0.007, respectively).
Conclusion: This study suggests different mechanisms of carcinogenesis are initiated by smoking, alcohol and
HPV. Our data propose higher phosphorylation of Akt at T308 as a reliable biomarker for smoking and alcohol
induced HNSCC progression and higher phosphorylation of Akt at S473 as a prognostic factor for HNSCC.
Keywords: pAkt T308, pAkt S473, HNSCC, Risk factors, Prognosis, Biomarker
Background
HNSCC (Head and Neck Squamous Cell Carcinoma) in-
cludes cancers that involve the oral cavity, pharynx and
larynx. Each year there are approximately 400 000 cases
of cancer of the oral cavity and pharynx, with 160 000
cancers of the larynx, resulting in approximately 300 000
deaths [1]. It is the sixth most common type of cancer
worldwide with a five year survival rate of 40-50%, which
has shown only moderate improvement over the last two
decades [2]. Two modifiable risk factors, tobacco use and al-
cohol consumption, are thought to explain approximately
75% of the incidence of HNSCC (up to 100 times higher for
both) [3]; another important risk factor is HPV infection,
which has been detected in around 20% of all cases [4].
Recent studies have focused on the genetic and epigen-
etic alterations of HNSCC, providing a better understand-
ing of the molecular events underlying the pathogenesis of
HNSCC [5,6]. One of the most frequently altered signaling
pathways in HNSCC is the PI3K/Akt cascade [6]. Akt, also
known as PKB, is a serine-threonine protein kinase and is
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central to the phosphatidylinositol 3-kinase (PI3K) signal-
ing pathway [7-9]. PI3K is activated by tyrosine-kinase
transmembrane receptors and other signaling intermedi-
ates, such as Ras oncogenes and G proteins [10]. PI3K
then phosphorylates PtdIns (4,5) P2 (PIP2) yielding PtdIns
(3,4,5) P3 (PIP3), which serves as an anchor for intracellular
proteins (primarily mediated by pleckstrin homology do-
mains), including Akt amongst others. Membrane-bound
Akt is phosphorylated at T308 in the catalytic domain by
the kinase PDK1 and at S473 in the regulatory domain by
mTORC2 [11,12]. Full Akt kinase activity is dependent upon
phosphorylation at both T308 and S473 residues and this is
greatly increased by growth factor receptor signaling [13].
PIP3 is converted back into PIP2 through the action of the
lipid phosphatase PTEN, thus terminating the PI3K-initiated
signal and avoiding further Akt activation [14]. Growth fac-
tor receptor over-expression [15,16], mutation and down-
regulation of PTEN protein [17] and amplification of the
PIK3CA gene (the gene coding for the catalytic unit of
PI3K) [18] can lead to increased Akt activity. Enhanced
Akt activity has indeed been found in 20 to 60% of tumor
samples and in the majority of HNSCC-derived cell lines
[18-21]. Once Akt is phosphorylated and activated, it is
capable of phosphorylating multiple substrates generating
diverse cellular processes, such as metabolism, prolifera-
tion, survival and protein synthesis [22].
An increasing number of mucosal changes and cellular
atypia occur over large areas of the carcinogen-exposed
upper aero-digestive tract epithelium, which initiate the
stepwise carcinogenesis process in HNSCC. Acquisition
of a transformed phenotype and accumulation of specific
molecular genetic events are associated with this process
[23-28]; yet histopathological evaluation remains the
time honored method in risk assessment of carcinoma
lesions. In a search for better biological models of risk,
Akt activation was recently identified as an early cellular
response to carcinogen exposure and may be a signifi-
cant step in environmental carcinogenesis [29]. Akt acti-
vation has also been found to correlate with squamous
cell carcinoma progression from normal epithelium to
invasive cancer [30].
These observations encouraged us to investigate the
role of demographic, pathological and major risk factors
(smoking, alcohol and HPV) of HNSCC patients on the
activation of Akt (phosphorylation of Akt at Threonine
308 and Serine 473) and to determine their prognostic
role.
Results
Analysis of patient details
58 HNSCC patient details were analyzed in this study. 33
(57%) were male and 25 (43%) female with ages ranging
from 36 to 97 years (median age 64 years). 42 (72%) were
smokers and 16 (28%) non-smokers. 7 patients (12%) were
non-drinkers, 21 (36%) medium or moderate drinkers and
30 (52%) were heavy drinkers. 31 (53%) patients had
negative and 27 (47%) had positive nodal metastasis.
Half of the cohort was HPV positive. 43 (74%) patients
had T1/T2 and 15 (26%) had T3/T4 tumor size with 5
(9%) of them grade I, 39 (67%) of them grade II and 14
(24%) of them grade III. These data are summarized in
Table 1.
Immunohistochemistry for Akt phosphorylation
Both normal and VEGF-positive carcinoma patient sam-
ples were stained with pAkt S473 and pAkt T308 anti-
bodies. Some samples which were highly stained for
pAkt S473 and pAkt T308 were then selected and tested
with the blocking peptide for the respective antibody
and were used as negative controls (Figure 1A). No
staining was observed in the blocking peptide treated tis-
sues and this confirmed the specific binding of the
antibodies.
Normal tissue samples were also regarded as negative
controls and the level of Akt phosphorylation at T308
was higher in the HNSCC group than the control (me-
dian 5.8 vs 2.0, P < 0.001) (Figure 1B). Normal tissue ad-
jacent to the tumors was also tested and the resultant
data indicated that there was very low or no pAkt T308/
pAkt S473 present (Figure 1C). There is also some evidence
to suggest higher levels of pAkt S473 in the cancer group
than the controls (P = 0.054) (Figure 1B). There is a statisti-
cally significant difference between pAkt T308 and pAkt
S473 levels in the cancer patients (pAkt T308, median 5.8
vs pAkt S473, median 0.3, P < 0.001) (Figure 1B). VEGFA is
not correlated with pAkt T308 (r = 0.062, P = 0.644) and
pAkt S473 (r = 0.181, P = 0.175). Table 1 compares the
characteristics between pAkt expression groups. All the
samples were found to be phosphorylated at Akt T308
so there is no ‘no phosphorylation’ group for this resi-
due. On the other hand, there is no ‘high phosphoryl-
ation’ group for pAkt S473.
Association of patient characteristics with Akt
phosphorylation
Smoking and alcohol were found to be independent risk
factors for phosphorylation of Akt at T308 (P = 0.022
and 0.027, respectively) but not for pAkt S473 (P = 0.449
and 0.968, respectively). HNSCC with nodal metastasis
was associated with a higher level of pAkt T308 than
HNSCC without nodal metastasis (P = 0.018). Smokers
and HNSCC with nodal metastasis were found to have
higher levels of Akt phosphorylated at T308 than non-
smokers (P = 0.022) and HNSCC without modal metas-
tasis (P = 0.018) patients, respectively. HPV-negative patients
exhibited higher levels of pAkt T308 compared to those who
were HPV positive (P = 0.028). There is some evidence to
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suggest that heavy drinking patients had higher levels of
pAkt T308 than medium drinkers (P = 0.063).
Adjusted by four independent variables, smoking, drink-
ing, nodal status and age, the general linear model ac-
counts for 65.2% (R2 = 0.652) of the total variation in pAkt
T308 levels (Table 2). This model’s significance statistics
for the F-statistic (P < 0.001) indicate that there is only
a very small chance that the observed correlation between
one or more of the independent variables and the dependent
variable is due solely to random sampling error.
Smoking (P = 0.027), drinking habit (P < 0.001) and age
(P = 0.031) showed a significant effect on the phosphor-
ylation of Akt at T308. Alcohol and age, alcohol and
nodal involvement, smoking and nodal involvement and
Table 1 Demographic, behavioral and pathological data by pAkt status
Akt T308 phosphorylation status Akt S473 phosphorylation status
n High Medium Low p Medium Low None p
(n = 40) (n = 8) (n = 10) (n = 5) (n = 30) (n = 23)
% % % % % %
Gender 0.109 0.737
Male 33 62 63 30 60 50 65
Female 25 38 37 70 40 50 35
Age 0.233 0.376
<65 years 30 50 50 60 80 43 57
≥65 years 28 50 50 40 20 57 43
Location 0.217 0.094
FOM 10 15 25 20 20 17 17
RMT 8 10 13 30 0 10 22
SP 5 10 0 10 40 10 0
Tong 27 53 50 20 20 47 53
Alv 4 5 0 20 0 10 4
Other 4 7 12 0 20 6 4
Tumor size 0.173 0.213
T1-T2 43 70 25 90 60 73 78
T3-T4 15 30 75 10 40 27 22
Grade 0.523 0.788
I 5 8 12 10 0 7 13
II 39 65 75 70 80 66 65
III 14 27 13 20 20 27 22
Lymph node metastasis 0.018 0.327
Positive 27 58 12 30 40 50 43
Negative 31 42 88 70 60 50 57
HPV status 0.028 0.301
Positive 29 40 63 80 40 43 61
Negative 29 60 37 20 60 57 39
Smoking 0.022 0.449
Yes 42 82 50 50 80 70 74
No 16 18 50 50 20 30 26
Alcohol 0.027 0.968
Non-drinker 7 10 0 30 0 17 9
Medium drinker 21 27 62 40 40 33 39
Heavy drinker 30 63 38 30 60 50 52
Note: The General linear model was used for hypothesis testing of the relationship between different variables and pAkt. The P value was obtained from
univariable analysis. Percentages represent the column percentages within variable so that the balance between the pAkt groups could be assessed.
Abbreviations: FOM Floor of the mouth, RMT Retromolar trigone, SP Soft palate, Tong Tongue, Alv Alveolus.
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smoking and alcohol are strongly correlated with the
phosphorylation of Akt at T308 in pairwise combination
(P = 0.009, 0.038, 0.049 and 0.052, respectively). More-
over, smoking, nodal involvement, age and alcohol, nodal
involvement, age also have a strong correlation with the
phosphorylation of Akt T308 (P = 0.019 and 0.022, re-
spectively). None of these independent variables corre-
lated with the phosphorylation of Akt at S473 (univariate
and multivariate, P > 0.05).
Non-drinking patients had lower levels of Akt phos-
phorylated at T308 and were more likely to be infected
by HPV than heavy drinkers (χ2 P = 0.044 and 0.007, re-
spectively). Also, HPV infected patients were shown to
have lower levels of Akt phosphorylated at T308 than
the non-infected patients (χ2 P = 0.028).
Survival Analysis
Levels of pAkt S473 and pAkt T308, as determined by
IHC, were examined for association with overall survival
using Cox’s proportional hazard model (Table 3). In
multivariate analysis, pAkt S473 level, tumor size, alcohol
consumption, age and patients’ HPV status had significant
effects on overall survival (P = 0.005, 0.005, 0.021, 0.007
and 0.004, respectively).
The rate of deaths in patients with medium levels of
phosphorylated Akt S473 was 438 times higher than in
those with none and 21.5 times higher than in those with
low levels (P = 0.001 and P = 0.036, respectively, Table 3).
Patients with tumors of size T3/T4 died more rapidly than
patients with tumors T1/T2 (HR = 15.2, P = 0.005). Death
rates in heavy drinkers were 49.4 times higher than
those who consumed no alcohol (P = 0.006). Older pa-
tients (65 years of age or over) were 46.8 times more
likely to die than those of 65 years of age (P = 0.007).
Finally, HPV positive patients were 89.4 times more likely
to die than those with a negative status (P = 0.004).
Discussion
To our knowledge this is the first report to show the re-
lationships between the major risk factors for HNSCC
Figure 1 VEGF positive carcinoma tissues were stained with pAkt antibodies. Blocking peptides were used to test the efficacy of the
antibodies and were tested on duplicate sections of those that had been highly stained for pAkt S473 and pAkt T308 using the antibodies alone.
These were used as negative controls. Normal tissues were also used as negative controls, where no staining was observed. All the representative
images were taken at x200 magnification except for those stained for pAkt T308, which were taken at x100. (A) pAkt S473 and pAkt T308 showed
more intense staining in HNSCC tissues compared to normal tissues (P < 0.05). (B) Phosphorylation of Akt at residue T308 was found to be
significantly higher in HNSCC patient samples compared to phosphorylation at S473 (P < 0.001). (C) Phosphorylation status of Akt in non-tumor
part of cancer tissues. Very weak or no phosphorylation of Akt at both T308 and S473 was observed in the non-tumor part of HNSCC tissues. The
arrow indicates the non-tumor area of the tissues. Images were captured at x200 magnification.
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(alcohol, smoking and HPV) and Akt activation (both at
residues T308 and S473) at the protein level using an
immunohistochemical staining method (IHC), in surgi-
cally resected specimens. Most studies to date have used
IHC to assess the prognostic value of Akt activation in
HNSCC, but have focused only on phosphorylation of
residue S473. As the differential phosphorylation of Akt
at the two sites may modulate downstream substrate se-
lectivity and subsequent bioactivity [13], it is not surpris-
ing that Akt phosphorylated at any single site could
perform certain cellular bioactivities. Two different mech-
anisms are involved in phosphorylating Akt, therefore
overexpression or amplification of any components in
these mechanisms may result in over-phosphorylation at
any one of the two sites. It is therefore worth studying the
phosphorylation status of Akt at both sites in HNSCC
specimens to elucidate their different roles.
As only VEGFA positive HNSCC biopsy samples were
selected in this study, no statistically significant correl-
ation was found between VEGF and pAkt. The present
study showed that Akt was significantly phosphorylated
at T308 in VEGF positive HNSCC rather than S473. Al-
cohol and smoking were positively correlated with pAkt
T308 activation but not with pAkt S473. Moreover, Akt
activated at T308 showed a significant relationship with
lymph node metastasis, which suggests that pAkt T308
may be concerned with invasion and metastasis. This
data is similar to our in vitro data concerning the migra-
tion of tumor cells in response to VEGF, which suggests
Table 3 COX proportional hazard model- time to death
Unadjusted HR Adjusted HR
HR 95% CI P HR 95% CI P
pAkt S473 Overall 0.168 0.005
Med:No 6.27 0.87, 45.3 0.069 438 10.9, 1755 0.001
Med:Low 1.83 0.38, 8.88 0.456 21.5 1.23, 376 0.036
Tumor size T3/T4:T1/T2 4.59 1.39, 15.2 0.013 15.2 2.28, 102 0.005
Alcohol Overall 0.005 0.021
Heavy:Non-drinker 15.4 2.74, 86.7 0.002 49.4 3.04, 801 0.006
Heavy:Moderate 3.19 0.62, 16.5 0.166 2.69 0.35, 20.8 0.343
Age ≥65:<65 5.41 1.17, 25.05 0.031 46.8 2.81, 781 0.007
HPV +ve:−ve 89.4 4.05, 1973 0.004
Gender F:M 1.40 0.42, 4.63 0.581
Tumor size Overall 0.310
Nodal status +ve: −ve 1.49 0.43, 5.10 0.529
Smoking No:Yes 1.45 0.42, 4.95 0.556
pAkt T308 Overall 0.984
Low:High 1.02 0.21, 4.92 0.985
Med:High 1.16 0.24, 5.63 0.858
Note: Unadjusted HR obtained from univariable analysis and adjusted HR from multivariable analysis after adjusting tumor size, alcohol, age, HPV and pAkt S473.
All the variables are categorical and HR = exp (B). Abbreviations: HR Hazard ratio, 95% CI 95% confidence interval.
Table 2 General Linear Model (Multivariate analysis)
Independent variables F P
Corrected model 4.06 <0.001
Smoking 5.30 0.027
Alcohol 10.56 <0.001
Nodal status 1.31 0.260
Age 4.98 0.031
Smoking * Alcohol 3.20 0.052
Smoking * Nodal status 4.12 0.049
Smoking * Age 0.01 0.919
Alcohol * Nodal status 3.56 0.038
Alcohol * Age 5.31 0.009
Nodal status * Age 2.80 0.102
Smoking * Alcohol * Nodal status 0.17 0.682
Smoking * Alcohol * Age 0.08 0.774
Smoking * Nodal status * Age 6.00 0.019
Alcohol * Nodal status * Age 5.73 0.022
R2 = 0.652
Note: After adjusting Smoking, Alcohol, Nodal Status and Age, this model
accounts for 65.2% of the total variations in pAkt T308 level. R2 = Coefficient of
determination, F = F-statistics.
Dependent variable: pAkt T308 score.
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that migration of oral adeno-squamous cancer cells is
dependent on Akt T308 phosphorylation. Our study also
disclosed that Akt phosphorylated at both residues con-
trols oral cancer cell motility [31], but it should be re-
membered that studies performed with cultured cells or
tissue models may produce different results. In vivo,
tumor progression requires both positive and reciprocal
feedback between the components of the tissue micro-
environment and cancer cells [32].
The activation of Akt in response to alcohol exposure is
an important contributor to the molecular effects of ex-
cessive alcohol consumption [33]. In 2003, West showed
that redundant Akt activation by nicotine and nicotine-
derived nitrosamine ketone (NNK) could contribute to
tobacco-related carcinogenesis [29]. A study by the Gon-
zalez group in 2005, revealed that Akt activation was cor-
related with concomitant PI3K accumulation and PTEN
down-regulation in HNSCC, reflecting an early biochem-
ical effect in response to nicotine [18]. Combined with
these data, our study supports the basic hypothesis that
Akt activation (especially at T308) is a key step in the pro-
gression of HNSCC caused by alcohol and smoking. HPV
infection, another risk factor for HNSCC, was found to be
negatively correlated with Akt activation at T308, as HPV
positive HNSCC patients showed lower levels of pAkt
T308. Non-drinking patients had lower levels of acti-
vated Akt at T308 too and there were more HPV posi-
tive patients among non-drinkers than amongst the
heavy drinkers. Earlier epidemiologic research supports
this data, that is non-smokers and light or non-drinkers
are more likely to have tumors positive for HPV than are
heavy smokers and drinkers [34]. Molinolo et al. [35]
showed in their study that HPV positive HNSCC patients
over-activate Akt at S473 and mTOR. Although we have
not found any association between HPV infection and
pAkt S473 activation, this may suggest that there are two
different mechanisms of cancer progression initiated by
alcohol, smoking and HPV. The Kelsey group study
(2007), strongly supports the emerging view that the
etiology of HPV related HNSCC is distinct from that
of HNSCC tumors associated with smoking and drink-
ing [36]. Increased Akt activation at T308 by excessive
alcohol and smoking may be responsible for cancer devel-
opment and progression, including metastasis, whereas
HNSCC by HPV infection may over-activate Akt at S473
and be responsible for poor survival.
In this study we show that increased pAkt S473 levels in
HNSCC are a strong predictor for poor patient outcome.
In the multivariate Cox proportional hazard model, ad-
justed for well recognized prognostic indicators (e.g. tumor
size and age), pAkt S473 status remained a strong pre-
dictor. This is corroborated by three other studies which
have shown that pAkt activated at S473 is associated with
poor prognosis in oral cancer [37-39]. Although further
molecular analysis is needed to investigate the mechan-
ism of smoking and alcohol related HNSCC development,
we can propose pAkt T308 as a reliable biomarker for
smoking and alcohol induced HNSCC progression.
Conclusions
The predictive role of Akt activation in HNSCC suggests
that targeting PI3K/Akt and mTORC2/Akt pathway along
with RTK (receptor tyrosine kinase) might be a useful
strategy for therapy in this disease. A large cohort with a
longer follow-up of pre-neoplastic and HNSCC lesions is
needed to more accurately define the role of Akt activa-
tion in carcinogenesis and to integrate this data into a risk
model for carcinoma development and progression. In
conclusion, our findings suggest that targeting Akt activa-
tion might be of interest as part of a combination therapy
in HNSCC, as described earlier [40].
Methods
Patients
Ethical approval (ID: LEC271/03) was granted for the
prospective collection of tissues which were stored at
the Tayside Tissue Bank. In total 64 HNSCC and 11 nor-
mal oral mucosal tissues (from non-tumor patients)
were collected from patients treated at Ninewells Hos-
pital Tayside. Baseline data obtained from patient charts
included age, sex, histology, site, drinking and smoking
status, nodal involvement, survival and follow-up data.
Patients were followed-up for a total of 66 months
(median, 40 months) after diagnosis.
Some continuous variables (such as age, drinking and
smoking status) were changed into categorical variables
in this study with clear justification (statistical and/or
clinical reasons). Age was grouped as ‘<65 years of age’
and ‘≥65 years’ because approximately 50% patients were
above/below 65 and a growing number of patients with
Head and Neck Squamous Cell Carcinoma (HNSCC)
are aged 65 and older [41]. Patients who consumed alco-
hol were referred to as ‘drinkers’ throughout this article.
Drinkers were categorized as non-drinkers, medium or
moderate drinkers (less than 7 units per week for women
and 14 units per week for men or occasional or social,
regarded as low risk group by NIAAA), and heavy
drinkers (over 7 units per week for women and 14 units
per week for men) according to the National Institute of
Alcohol Abuse and Alcoholism [42]. Smoking status was
classified as non- or light smokers (less than 5 cigarettes
per day) and smokers (more than 5 cigarettes per day)
after reviewing the literature [43-45].
HNSCC tissues were stained for VEGFA expression by
IHC [31] and tissues with IHC scores of more than 3
were selected and regarded as positive. Tissues were also
analyzed for HPV DNA by PCR, automated DNA se-
quencing and the SPF10-LiPA25 method [46].
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Immunohistochemistry
The paraffin-embedded tissues were cut into 5 μm sections,
dewaxed in xylene and then rehydrated in serial ethanol
solutions, before washing in distilled water for 5 minutes.
58 VEGFA positive HNSCC and 11 normal mucosal sam-
ples were then probed with pAkt T308 (#2965) and pAkt
S473 (#4060) antibodies according to the manufacturer’s
instructions (Cell Signaling Technology Inc., Danvers, MA,
USA). In brief, after the deparaffinization and rehydra-
tion process, antigens were unmasked by boiling in
10mM Sodium citrate buffer (pH 6.0) using a micro-
wave, followed by maintenance at a sub-boiling temperature
for 10 minutes and then cooling for 30 minutes on the
bench top. 3% (v/v) H2O2 was then used as a peroxidase
blocker and TBST (Tris buffered saline with 0.1% v/v Tween
20) for washing. Sections were then blocked with 5% (v/v)
normal goat serum (NGS) plus TBST for 1 hour at room
temperature. Sections were then incubated with antibodies
against pAkt S473 (1:50) and pAkt T308 (1:50) diluted in
5% (v/v) NGS/TBST in a humidified chamber overnight at
4°C. After equilibration, sections were then washed three
times with TBST and then incubated in signal stain boost
detection reagent (HRP, rabbit #8114, Cell Signaling Tech-
nology) for 30 minutes at room temperature. Visualization
was achieved by incubation with 3,3’-diaminobenzidine
(DAB) (Sigma-Aldrich, MO, USA) for 5 minutes and
counterstaining with Mayer’s haematoxylin (Sigma) and
eosin. Rehydration and mounting processes were then
followed as described in the instruction manual (Cell
Signaling Technology). Normal oral mucosal tissues were
used as negative controls. The pAkt S473 and pAkt T308
antibodies were blocked using the respective blocking
peptide (#1140 and 1145B, respectively, Cell Signaling
Technology) by adding twice the volume of peptide as
volume of antibody used, in a total volume of 100 μl.
These tissues were also used as negative control.
IHC score
According to the scoring systems that have been re-
ported previously in the literature, [47,48] with some
modifications, pAkt staining scoring was performed as
follows: stained sections were visualized using a light
microscope at high power field and were evaluated by
three observers without prior knowledge of the patients’
characteristics. An intra-class correlation (inter-observer
correlation) analysis using a mixed model and testing for
consistency gave a Chronbach’s alpha of more than 0.8.
The cells showing cytoplasmic and/or nuclear staining
were judged as positive. Five high power fields were se-
lected randomly under the microscope. The average per-
centage of positive staining was calculated for each field.
The average percentage of tissue staining was designated
as 0 when less than 10% was stained, 1 when 10-25%, 2
when 25-50%, 3 when 50-75% and 4 when >75% of
tissues stained. The intensity of tissue staining positively
was categorized as follows: 0, no appreciable staining in
tissues; 1, barely detectable staining as compared with
stromal elements; 2, readily appreciable brown staining
distinctly marking cell cytoplasm and/or nucleus; and 3,
dark brown staining in tissues completely obscuring cyto-
plasm and/or nucleus. Scoring was performed according
to the product of staining intensity and average percentage
of tissue staining positively ranging from 0–12. In the
following analysis, the level of Akt phosphorylation
was evaluated using the pAkt index either as a con-
tinuous variable directly or categorized as no phos-
phorylation (IHC score 0), low phosphorylation (IHC
score 0.1-2.0), medium phosphorylation (IHC score 2.1-5.0),
high phosphorylation (IHC score 5.1-12.0) after reviewing a
number of studies [37,49-60].
Statistics
Data were analyzed using the statistical package IBM
SPSS 19.0. Comparisons between the tissues (HNSCC
and normal) regarding the Akt phosphorylation were
carried out using a Mann–Whitney U test. Associations
between categorical demographic, pathological and be-
havioral factors were investigated using cross tabulation
and Pearson chi-square test. Associations between these
variables and continuous immunohistochemical parame-
ters were evaluated with general linear models (both
univariate and multivariate). Bonferroni’s correction for
multiple comparisons was applied where appropriate.
Patients’ characteristics and pAkt IHC score were ana-
lyzed for possible association with overall survival by uni-
variate and multivariate Cox proportional hazard models.
Overall survival was defined as the time between diagnosis
date and death or last follow-up date. Initially, explanatory
factors were screened for univariate associations with
death, using a method appropriate to the distribution of
the data. If the two-sided P value was <0.300 for any vari-
able it was considered as a candidate in multiple regres-
sion models (Hosmer-Lemeshow criterion). Variables with
P ≥ 0.300 were discarded at this stage. The assumption of
proportional hazards was checked for independent vari-
ables by plotting the logarithm of the cumulative hazards
functions. Starting with the set of variables identified for
inclusion from the previous steps, a multiple Cox regres-
sion model was built using a step-wise approach.
All tests were two-sided, using the 5% significance
level.
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